Quanterix Corporation

About Quanterix Corporation

Quanterix is a company focused on ultrasensitive biomarker detection to transform healthcare. Their mission is to empower researchers with precision instruments and assay kits, enabling earlier disease detection, better prognoses, and enhanced treatment methods across various therapeutic areas including neurology, oncology, and infectious diseases.

Products & Services

Simoa® Technology:A digital health solution for ultrasensitive biomarker detection, enabling earlier disease detection and research in multiple therapeutic areas.

Simoa® Assay Kits:Ready-to-use kits for protein quantitation compatible with Quanterix instruments, offering enhanced consistency and sensitivity.

Simoa® HD-X Analyzer:An automated immunoassay platform for ultrasensitive biomarker detection.

Quanterix SR-X® Biomarker Detection System:A system for detecting biomarkers with high sensitivity.

SP-X® Imaging and Analysis System:An imaging and analysis system for biomarker research.

Lucent Diagnostics:A division offering the LucentAD blood test for p-Tau detection in clinical settings.

Homebrew Custom Assay Development:Flexible solutions for developing custom ultrasensitive immunoassays for specialized research.

Simoa® Accelerator Laboratory:Provides protein biomarker testing and custom assay development services.

Nova Beads™:A product line supporting assay development.

Uman NF-Light™:ELISA kits and antibodies for neurofilament light chain detection.

Specialties

Ultrasensitive Biomarker Detection Neurology Research (Alzheimer's, Parkinson's, Multiple Sclerosis, TBI) Oncology Research Immunology/Inflammation Research Infectious Disease Research (including HIV and COVID-19) Cardiology Research Digital Health Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Notes Purchase T: - FT: Convertible Notes Purchase	A: 30000000 MR: - FA: $30 million FAN: 30000000	D: 2025-04-14 FD: 2025-04-14	-

Convertible Notes Purchase Latest

2025-04-14

$30.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Masoud Toloue, PhD

Chief Executive Officer

E

Erica Bell

Chief People Officer

N

Naren Bhat

SVP, Corporate Development & Strategy

L

Laurie Churchill

SVP and General Counsel

D

Darrin Crisitello

SVP and Chief Commercial Officer

M

Michael Miller

Chief Operating Officer

View 13 more team members with Pro

Unlock Full Team Directory

Recent News